Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) posted its quarterly earnings results on Friday. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.08, Zacks reports. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.
Daiichi Sankyo Stock Performance
Daiichi Sankyo stock traded up $0.88 during midday trading on Friday, hitting $17.44. 96,936 shares of the company were exchanged, compared to its average volume of 305,907. The firm has a market capitalization of $32.49 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.73 and a beta of -0.11. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $24.77. The business has a fifty day simple moving average of $17.78 and a two-hundred day simple moving average of $17.69. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.
Wall Street Analysts Forecast Growth
DSNKY has been the subject of several research analyst reports. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce”.
Read Our Latest Stock Analysis on DSNKY
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Read More
- Five stocks we like better than Daiichi Sankyo
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
